Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension
Jean‐Luc Vachiéry(Erasmus Hospital), Robert Naeije(Erasmus Hospital), Hunter Gillies(Pfizer (United Kingdom)), Naoto Hayashi(Pfizer (United Kingdom)), Xiang Gao(Hebei Medical University), Gary Layton(University of Geneva), Sandrine Huez(Erasmus Hospital)
Cited by 73
Related Papers
Contemporary Management of Acute Right Ventricular Failure: A Statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology
|European Journal of Heart Failure|2016|708
P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2014|488
High-Altitude Pulmonary Edema Is Initially Caused by an Increase in Capillary Pressure
|Circulation|2001|468
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Oral Sildenafil Citrate in Treatment-Naive Children With Pulmonary Arterial Hypertension
|Circulation|2011|375
Prospective study of dietary pattern and risk of Parkinson disease
|American Journal of Clinical Nutrition|2007|342